NLRP3 and diabetic kidney disease: For example, animals with the human A350V gain-of-function mutation and/or deletion of NLRP3 in podocytes have shown that activation of this inflammasome is sufficient to promote the glomerular damage observed in animals with diabetic kidney disease (115).